TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Business of Childcare Homes & Child Health: Innovations for Nurturing Growth
Brief Summary: The purpose of this project is to evaluate the efficacy of a 9-month Family Child Care Home (FCCH)-based intervention, Keys to Healthy Family Child Care Homes, to increase the physical activity and improve the diet quality of children (1.5 to 4.9 years).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Teacher-Delivered Weight Control Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Teacher-Delivered General Health Intervention | Intervention Type: BEHAVIORAL; Name: Teacher-Delivered Weight Control Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Teacher-Delivered General Health Intervention; Assigned to Arm(s): 2
B: Arm Label: CHild Inhibitory Control Play (CHIC) Play; Type: EXPERIMENTAL; Interventions: Behavioral: CHild Inhibitory Control (CHIC) Play | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention control | Intervention Type: BEHAVIORAL; Name: CHild Inhibitory Control (CHIC) Play; Assigned to Arm(s): CHild Inhibitory Control Play (CHIC) Play | Intervention Type: BEHAVIORAL; Name: Attention control; Assigned to Arm(s): Attention control
C: Arm Label: Healthy Lifestyles Group; Type: EXPERIMENTAL; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Arm Label: Healthy Business Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Intervention Type: BEHAVIORAL; Name: Keys to Healthy Family Child Care Homes; Assigned to Arm(s): Healthy Business Group, Healthy Lifestyles Group
D: Arm Label: Nutrition and Physical Activity Training; Type: EXPERIMENTAL; Interventions: Behavioral: NAP-SACC Child Care Wellness Program | Arm Label: Delayed Intervention Group; Type: OTHER; Interventions: Behavioral: NAP-SACC Child Care Wellness Program | Intervention Type: BEHAVIORAL; Name: NAP-SACC Child Care Wellness Program; Assigned to Arm(s): Delayed Intervention Group, Nutrition and Physical Activity Training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Business of Childcare Homes & Child Health: Innovations for Nurturing Growth
Brief Summary: The purpose of this project is to evaluate the efficacy of a 9-month Family Child Care Home (FCCH)-based intervention, Keys to Healthy Family Child Care Homes, to increase the physical activity and improve the diet quality of children (1.5 to 4.9 years).


Options:
A: Arm Label: WIC Program Participants; Type: N/A; Interventions: N/A
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
C: Arm Label: Healthy Lifestyles Group; Type: EXPERIMENTAL; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Arm Label: Healthy Business Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Intervention Type: BEHAVIORAL; Name: Keys to Healthy Family Child Care Homes; Assigned to Arm(s): Healthy Business Group, Healthy Lifestyles Group
D: Arm Label: Healthy eating blog (HEB); Type: EXPERIMENTAL; Interventions: Behavioral: Healthy eating blog | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy eating blog; Assigned to Arm(s): Healthy eating blog (HEB)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Business of Childcare Homes & Child Health: Innovations for Nurturing Growth
Brief Summary: The purpose of this project is to evaluate the efficacy of a 9-month Family Child Care Home (FCCH)-based intervention, Keys to Healthy Family Child Care Homes, to increase the physical activity and improve the diet quality of children (1.5 to 4.9 years).


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Childhood Obesity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Childhood Obesity; Assigned to Arm(s): Treatment
B: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Start | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy Start; Assigned to Arm(s): Intervention arm
C: Arm Label: HOME Plus Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: HOME Plus intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HOME Plus intervention; Assigned to Arm(s): HOME Plus Intervention
D: Arm Label: Healthy Lifestyles Group; Type: EXPERIMENTAL; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Arm Label: Healthy Business Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Intervention Type: BEHAVIORAL; Name: Keys to Healthy Family Child Care Homes; Assigned to Arm(s): Healthy Business Group, Healthy Lifestyles Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Business of Childcare Homes & Child Health: Innovations for Nurturing Growth
Brief Summary: The purpose of this project is to evaluate the efficacy of a 9-month Family Child Care Home (FCCH)-based intervention, Keys to Healthy Family Child Care Homes, to increase the physical activity and improve the diet quality of children (1.5 to 4.9 years).


Options:
A: Arm Label: NOURISH-T; Type: EXPERIMENTAL; Interventions: Behavioral: NOURISH-T | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: NOURISH-T; Assigned to Arm(s): NOURISH-T | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Childhood Obesity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Childhood Obesity; Assigned to Arm(s): Treatment
C: Arm Label: Healthy Lifestyles Group; Type: EXPERIMENTAL; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Arm Label: Healthy Business Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Intervention Type: BEHAVIORAL; Name: Keys to Healthy Family Child Care Homes; Assigned to Arm(s): Healthy Business Group, Healthy Lifestyles Group
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of the MedSentry System on Medication Adherence for Patients With Congestive Heart Failure: A Pilot Study
Brief Summary: The goal of this pilot study to evaluate the effect of the MedSentry system, a multi-faceted medication adherence device and reminder system, on medication adherence and clinical outcomes in heart-failure (HF) patients. We will also evaluate the usability and satisfaction derived from using this system.

We hypothesize that:

1. The use of the MedSentry system will improve medication adherence in patients with a discharge diagnosis of HF.
2. The improvement in adherence correlates with fewer hospitalizations and emergency department (ED) visits.
3. The improvement in adherence correlates with better health-related quality of life.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention
B: Arm Label: Machine and NCC; Type: EXPERIMENTAL; Interventions: Other: MD2 machine and nurse care coordination | Arm Label: Medplanner and NCC; Type: EXPERIMENTAL; Interventions: Other: Medplanner and Nurse Care Coordination | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MD2 machine and nurse care coordination; Assigned to Arm(s): Machine and NCC | Intervention Type: OTHER; Name: Medplanner and Nurse Care Coordination; Assigned to Arm(s): Medplanner and NCC
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MedSentry System; Type: EXPERIMENTAL; Interventions: Device: MedSentry System | Intervention Type: DEVICE; Name: MedSentry System; Assigned to Arm(s): MedSentry System
D: Arm Label: STRIP intervention; Type: EXPERIMENTAL; Interventions: Other: STRIP intervention | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: STRIP intervention; Assigned to Arm(s): STRIP intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Active-Controlled, Parallel Group, Double-Blind Study to Compare the Efficacy and Safety of Tramadol HCl/Acetaminophen ER and IR in Subjects Who Complain of Moderate to Severe Postoperative Pain
Brief Summary: The purpose of this study is to compare the efficacy and safety of extended release (ER) tramadol hydrochloride (HCl)/acetaminophen with immediate release (IR) tramadol HCl/acetaminophen in participants with moderate to severe (very serious, life threatening) postoperative pain.


Options:
A: Arm Label: COV155; Type: EXPERIMENTAL; Interventions: Drug: COV155 | Intervention Type: DRUG; Name: COV155; Assigned to Arm(s): COV155
B: Arm Label: LAYLA; Type: EXPERIMENTAL; Interventions: Drug: LAYLA tablet | Arm Label: JOINS; Type: ACTIVE_COMPARATOR; Interventions: Drug: JOINS tablet | Intervention Type: DRUG; Name: LAYLA tablet; Assigned to Arm(s): LAYLA | Intervention Type: DRUG; Name: JOINS tablet; Assigned to Arm(s): JOINS
C: Arm Label: Tramadol Hydrochloride/Acetaminophen ER; Type: EXPERIMENTAL; Interventions: Drug: Tramadol HCl/Acetaminophen ER | Arm Label: Tramadol HCl/Acetaminophen IR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tramadol HCl/Acetaminophen IR | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen ER; Assigned to Arm(s): Tramadol Hydrochloride/Acetaminophen ER | Intervention Type: DRUG; Name: Tramadol HCl/Acetaminophen IR; Assigned to Arm(s): Tramadol HCl/Acetaminophen IR
D: Intervention Type: DRUG; Name: Diclofenac sodium gel 1%; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determination of Changes in Total Body Stores of Vitamin A in Response to Orange Maize Consumption by Zambian Children
Brief Summary: Determination of liver stores of vitamin A will be determined before and after consumption of high pro-vitamin A orange maize, compared to low provitamin A white maize.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vitamin A | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vitamin A | Intervention Type: BIOLOGICAL; Name: Vitamin A; Assigned to Arm(s): 1, 2
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): N/A
D: Arm Label: Orange maize; Type: EXPERIMENTAL; Interventions: Other: Orange maize feeding | Arm Label: Blue vitamin A group; Type: ACTIVE_COMPARATOR; Interventions: Other: Vitamin A supplement | Arm Label: White; Type: PLACEBO_COMPARATOR; Interventions: Other: Oil only | Intervention Type: OTHER; Name: Orange maize feeding; Assigned to Arm(s): Orange maize | Intervention Type: OTHER; Name: Vitamin A supplement; Assigned to Arm(s): Blue vitamin A group | Intervention Type: OTHER; Name: Oil only; Assigned to Arm(s): White

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determination of Changes in Total Body Stores of Vitamin A in Response to Orange Maize Consumption by Zambian Children
Brief Summary: Determination of liver stores of vitamin A will be determined before and after consumption of high pro-vitamin A orange maize, compared to low provitamin A white maize.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A or Beta-Carotene Supplements; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Orange maize; Type: EXPERIMENTAL; Interventions: Other: Orange maize feeding | Arm Label: Blue vitamin A group; Type: ACTIVE_COMPARATOR; Interventions: Other: Vitamin A supplement | Arm Label: White; Type: PLACEBO_COMPARATOR; Interventions: Other: Oil only | Intervention Type: OTHER; Name: Orange maize feeding; Assigned to Arm(s): Orange maize | Intervention Type: OTHER; Name: Vitamin A supplement; Assigned to Arm(s): Blue vitamin A group | Intervention Type: OTHER; Name: Oil only; Assigned to Arm(s): White
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer
Brief Summary: The trial will evaluate the optimal treatment with nab-paclitaxel in combination with either carboplatin or gemcitabine for patients with triple negative breast cancer.


Options:
A: Arm Label: 6 cycles of PC adjuvant chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel Cisplatin | Arm Label: 3 cycles of FEC followed by 3 cycles of Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T) | Intervention Type: DRUG; Name: Paclitaxel Cisplatin; Assigned to Arm(s): 6 cycles of PC adjuvant chemotherapy | Intervention Type: DRUG; Name: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T); Assigned to Arm(s): 3 cycles of FEC followed by 3 cycles of Docetaxel
B: Arm Label: Carboplatin + background treatment; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: background treatment | Arm Label: background treatment only; Type: ACTIVE_COMPARATOR; Interventions: Drug: background treatment | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + background treatment | Intervention Type: DRUG; Name: background treatment; Assigned to Arm(s): Carboplatin + background treatment, background treatment only
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: nab-Paclitaxel, Drug: Gemcitabine | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: nab-Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: nab-Paclitaxel; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B
D: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN ASIAN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Brief Summary: The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.


Options:
A: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
B: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 5mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 10mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5mg BID CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10mg BID CP-690,550
D: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN ASIAN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Brief Summary: The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
B: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 5mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 10mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5mg BID CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10mg BID CP-690,550
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: C